Browse studies, page 121
Page 121 of 1,286, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis The New England journal of medicine, 2019
- Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects Clinical pharmacology in drug development, 2016
- Evaluation of Eluxadoline Effect on Cardiac Repolarization Clinical pharmacology in drug development, 2018
- Clinical assessment of drug-induced QT prolongation in association with heart rate changes Clinical pharmacology and therapeutics, 2005
- Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects Antimicrobial agents and chemotherapy, 2019
- Lack of Effect of Rivipansel on QTc Interval in Healthy Adult African American Male Subjects Journal of clinical pharmacology, 2017
- An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study Clinical and translational science, 2022
- A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2021
- Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease Infection, 2016
- Effects of Bardoxolone Methyl on QT Interval in Healthy Volunteers Cardiorenal medicine, 2019
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023
- Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study Clinical pharmacology in drug development, 2021
- Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304) Annals of surgery, 2013
- Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects Clinical pharmacology in drug development, 2019
- Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects Journal of pharmacokinetics and pharmacodynamics, 2016
- Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations British journal of clinical pharmacology, 2022
- A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis The New England journal of medicine, 2022
- Omadacycline for Community-Acquired Bacterial Pneumonia The New England journal of medicine, 2019
- Ionophore-based potentiometric PVC membrane sensors for the determination of moxifloxacin Egyptian Journal of Chemistry, 2024
- Widespread rash in a 45-year-old woman after moxifloxacin administration JAAD Case Reports, 2024
- What are the risks and benefits of administering an 800 mg dose of moxifloxacin? Zenodo (CERN European Organization for Nuclear Research), 2026
- A facile and eco-friendly simultaneous quantification LC-TQ-MS/MS approach for N-Nitroso Moxifloxacin and di-nitroso pyrrolopiperidine in Moxifloxacin tablets and eye drops Green Analytical Chemistry, 2024
- Electrochemical Hydrogen Peroxide Generation and Removal of Moxifloxacin by Electro-Fenton Process Black Sea Journal of Engineering and Science, 2024
- Amelioration of Moxifloxacin-Induced Hepatotoxicity in Rats by Vitamin C and L-Carnitine FishTaxa - Journal of Fish Taxonomy, 2025
- Electrochemical Sensor Based on Molecularly Imprinted Polymer for the Detection of Moxifloxacin Russian Journal of Electrochemistry, 2024
- In-vitro Activity of Moxifloxacin against Theileria annulata - A Preliminary Study Indian Journal of Animal Research, 2026
- Evaluation of the chemotherapeutic efficacy of moxifloxacin in experimental colibacteriosis of chickens International Journal of Veterinary Medicine, 2026
- Fate of in vitro cultured Mycobacterium abscessus populations when exposed to moxifloxacin Frontiers in Microbiology, 2024
- Formulation and evaluation of moxifloxacin loaded ocular In - situ gels Future Journal of Pharmaceuticals and Health Sciences, 2024
- Efficacy of intracameral moxifloxacin versus topical moxifloxacin in preventing acute endophthalmitis after cataract surgery by phacoemulsification. Journal of Ayub Medical College Abbottabad, 2024
- Quality control testing with method development and validation of moxifloxacin Current Trends in Pharmacy and Pharmaceutical Chemistry, 2026
- Comparison of the Efficacy of Moxifloxacin Preparations in the Therapy of Conjunctivitis Ophthalmology in Russia, 2025
- Study of the effectiveness of Moxifloxacin in experimental colibacteriosis of laboratory animals International Journal of Veterinary Medicine, 2025
- Moxifloxacin Causing Lazy Heart: A Case Report Journal of Clinical Case Reports and Studies, 2025
- Durch Moxifloxacin-Augentropfen induziertes Hornhautödem Optometry & contact lenses, 2024
- Immunomodulatory Effects and Protection in Sepsis by the Antibiotic Moxifloxacin Antibiotics, 2024
- Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Ophthalmologically and Clinically Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants ClinicalTrials.gov · COMPLETED, 2026
- A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects ClinicalTrials.gov · COMPLETED, 2025
- A Phase 1, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Design Thorough QT Study With Nested Crossover to Investigate the Potential of TAK-279 to Prolong the QTc Interval in Adult Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Phase 1, Randomized, Double-Blind Study to Compare the Effect of Omadacycline PO Versus Moxifloxacin PO on the Gut Microbiota in Healthy Adult Volunteers ClinicalTrials.gov · COMPLETED, 2024
- A Phase 1, Partially Blinded, Randomized, Crossover Study to Evaluate the Pharmacokinetics and QT/QTc Interval of ESK-001 Compared to Placebo and Moxifloxacin in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema and Retinal Vein Occlusion Patients ClinicalTrials.gov · COMPLETED, 2026
- A Randomized, Single-blind, Placebo-controlled, Four-way Crossover Thorough QT Study to Investigate the Effect of KP-001 on the QT/QTc Interval Using Open-label Moxifloxacin as an Active Control, in Adult Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2025
- Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2026
- Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis ClinicalTrials.gov · COMPLETED, 2025
- Phase 1, Randomized, Double-Blind Four-Period Crossover, Thorough QT/QTc Study to Evaluate the Effects of EDP-938 on Cardiac Repolarization in Healthy Adults ClinicalTrials.gov · COMPLETED, 2025
- A Randomized, Double-Blind, Placebo- and Positive-Controlled (Moxifloxacin), Parallel Study With a Nested Crossover to Assess the Effect of Multiple Oral Therapeutic and Supratherapeutic Doses of BIIB091 on Cardiac Repolarization in Healthy Participants ClinicalTrials.gov · COMPLETED, 2025
- The Effect of Gland Expression on the Regeneration of Meibomian Gland ClinicalTrials.gov · COMPLETED, 2025
- A Phase 1 Placebo-and Active-Controlled Crossover Study of the Potential for Cardiac Repolarization Effects Following Single Dose of ABBV-CLS-7262 in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Enpatoran on the QTc (Corrected QT) Interval in Healthy Adult Participants ClinicalTrials.gov · COMPLETED, 2024
- Phase I Clinical Study, Evaluating Safety and Tolerability of PRO-232 an Ophthalmic Solution, Versus Placebo, When Applied to the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers ClinicalTrials.gov · COMPLETED, 2024
- A Phase 1, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, Parallel Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants ClinicalTrials.gov · COMPLETED, 2024
- A Study to Assess the Effect of Etavopivat on Cardiac Repolarisation in Healthy Participants ClinicalTrials.gov · COMPLETED, 2025
- A Phase 1, Two-Part, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986278 (Part A) and a Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization (Part B) in Healthy Participants ClinicalTrials.gov · COMPLETED, 2025
- A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial With Moxifloxacin as Positive Control to Evaluate the Effects of Multiple Subcutaneous Doses of BI 456906 in a Titration Scheme on Cardiac Safety Parameters in (Otherwise) Healthy Male and Female Subjects With Overweight/Obesity ClinicalTrials.gov · COMPLETED, 2025
- A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive-controlled, Placebo-controlled, Parallel, Nested-crossover (Moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants ClinicalTrials.gov · COMPLETED, 2025
- A Single-Center, Randomized, Partially Double-Blind, Placebo- and Active-Controlled, Four-period Crossover, Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity ClinicalTrials.gov · COMPLETED, 2026
- A Double-Blind, Placebo-Controlled and Active-controlled Trial to Evaluate the Effect of a Supratherapeutic Dose of MK-8527 on the QTc Interval in Healthy Adult Participants ClinicalTrials.gov · COMPLETED, 2025
- Thorough QT Study to Evaluate the Effects of BI 1015550 as Single Doses Following Oral Administration on Cardiac Safety Parameters (Double-blind, Randomized, Placebo-controlled, Five-period Crossover, With Open-label Moxifloxacin as Positive Control) in Healthy Male and Female Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants ClinicalTrials.gov · COMPLETED, 2026
- Effects of Iclepertin on the QT Interval Following Oral Administration in Healthy Male and Female Subjects (a Double-blind, Randomised, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial, With Moxifloxacin as Positive Control) ClinicalTrials.gov · COMPLETED, 2024
- A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-Way Crossover Phase I Thorough QTc Study to Investigate the Effect on QTcF of Single Doses of Baxdrostat Compared With Placebo, Using Open-label Moxifloxacin as a Positive Control, in Healthy Participants ClinicalTrials.gov · COMPLETED, 2024
- A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2024
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. ClinicalTrials.gov · COMPLETED, 2026
- Validation of HPLC-UV for simultaneous analysis of moxifloxacin and ciprofloxacin in peritoneal fluid Tropical Journal of Pharmaceutical Research, 2025
- Moxifloxacin and its USE in odontogenic infections. an alternative for patients with penicillin allergies? literature review International Journal of Advanced Research, 2025
- Use of soybean meal-based moxifloxacin pellets in equine nutrition and health Frontiers in Animal Science, 2025
- Comparative study of the microbiological activity of pazufloxacin, levofloxacin and moxifloxacin Meditsinskiy sovet = Medical Council, 2025
- Analysis of the Treatment Plan for Q-T Interval Prolongation Caused by Moxifloxacin in One Case Malaysian Journal of Medical Research, 2025
- Toxic epidermal necrolysis induced by moxifloxacin and exacerbated by clindamycin in an elderly patient: A case report Frontiers in Medicine, 2025
- In situ grown petal-like La-doped FeCo-layered double hydroxide on carbon felt for enhanced moxifloxacin hydrochloride removal via heterogeneous electro-Fenton process Chemosphere, 2024
- Removal of Moxifloxacin from Aqueous Solutions Using GO/Cr-MOFs Journal of Physical Chemistry A, 2024
- Fluid-Specific Detection of Environmental Pollutant Moxifloxacin Hydrochloride Utilizing a Rare-Earth Niobate Decorated Functionalized Carbon Nanofiber Sensor Platform Environmental Research, 2024
- Co/Cd-MOF-Derived Porous Carbon Materials for Moxifloxacin Adsorption from Aqueous Solutions Molecules, 2024
- Experience With Four-Month Rifapentine and Moxifloxacin–Based Tuberculosis Treatment in San Francisco Open Forum Infectious Diseases, 2024
- Treatment of Drug-Resistant Tuberculosis with Bedaquiline, Pretomanid, Linezolid with or Without Moxifloxacin (BPaL/M): Feasibility and Implementation Challenges in Western Canada Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2025
- Idiosyncratic Drug-Induced Neutropenia Following Pantoprazole, Moxifloxacin Hydrochloride, and Rifabutin Treatment for Helicobacter pylori: A Case Report Cureus, 2025
- MIM1 – a selective Mcl-1 protein inhibitor augments the proapoptotic activity of moxifloxacin toward MDA-MB-231 triple-negative breast cancer cells – a preliminary in vitro study Pharmacological Reports, 2025
- Successful maintenance therapy with moxifloxacin for disseminated nocardiosis caused by Nocardia farcinica in a patient with Cushing's syndrome Diagnostic microbiology and infectious disease, 2025
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin Treatment for Multi-Drug Resistant Extrapulmonary Tuberculosis in Canada: A Report Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2025
- Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment Pharmaceutics, 2025
- Adjunctive intravitreal anti-vascular endothelial growth factor and moxifloxacin for treating a large choroidal tuberculoma Indian Journal of Ophthalmology - Case Reports, 2025
- A Fourier‐Transform Infrared Spectroscopy‐Based Simple, Rapid, and Direct Quantification Assay for Moxifloxacin Journal of Spectroscopy, 2025
- Cost-effectiveness of omadacycline versus moxifloxacin as the initial treatment for community-acquired bacterial pneumonia in China International Journal of Clinical Pharmacy, 2025
- Formulation and evaluation of moxifloxacin-loaded proniosomal gel for ocular delivery Journal of Applied Pharmaceutical Research, 2025
- Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak Investigative Ophthalmology and Visual Science, 2025
- Hansen’s disease patient in Ohio successfully treated with a monthly rifampin, minocycline, and moxifloxacin regimen: a case report ASM case reports, 2025
- In vitro antibiofilm efficacy of ertapenem, tobramycin, and moxifloxacin against biofilms grown in a glass bead or CDC Biofilm Reactor®. PLoS ONE, 2025
- Safety, efficacy and feasibility of preventive treatment for drug-resistant tuberculosis with moxifloxacin or bedaquiline medRxiv, 2025
- Bilateral Acute Iris Transillumination Following Systemic Moxifloxacin Intake in the Greek Population Ophthalmology and Therapy, 2025
- Case Report: Drug-induced pneumonia caused by moxifloxacin and a literature review Frontiers in Medicine, 2025
- QbD-derived development of multilayer cellulose based polymeric coated extended-release gastroretentive effervescent floating pellets of moxifloxacin and its in silico PBPK modeling International Journal of Biological Macromolecules, 2025
- Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries IJTLD open, 2025
- Improvement of Pharmacopeial High-Performance Liquid Chromatography Method for Determination of Enantiomeric Purity of Moxifloxacin Drug Substance Journal of Separation Science, 2025
- Cationized gelatin-sodium alginate polyelectrolyte nanoparticles encapsulating moxifloxacin as an eye drop to treat bacterial keratitis International Journal of Biological Macromolecules, 2024
- Voltammetry Determination of Moxifloxacin, Paracetamol, and Vitamin C in Serum Samples Using PEDOT/CNT‐ILC/Fe3O4 Nanocomposite Sensor ChemistrySelect, 2025
- Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment Frontiers in Pharmacology, 2025
